n.a. (ELN)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)
Health Winners & Losers: Amylin

Health Winners & Losers: Amylin

Gains by Cephalon and Genzyme help boost the Amex biotech index. Amylin shares fall 1.7% after talks about pancreatitis and diabetes drug Byetta.

Pfizer Licenses Medivation Alzheimer's Drug

Pfizer will pay $225 million up front to gain worldwide marketing rights to Dimebon.

Health Winners & Losers: Biogen Idec, Elan

The FDA will update the companies' MS drug prescription.

Biogen, Elan Drug Gets New FDA Warning

Multiple sclerosis treatment Tysabri may cause a deadly brain infection whether used alone or with other treatments.

Top Three Activist Plays

Large shareholders are clamoring for change at these companies; their bets may be worth piggybacking.

Health Winners & Losers: Forest Labs

Health Winners & Losers: Forest Labs

The company was the best performer on the Amex Pharmaceuticals Index Friday.

Feuerstein's Biotech-Stock Mailbag: Titan

Feuerstein's Biotech-Stock Mailbag: Titan

Why Titan Pharma needs a development partner. And disparate outlooks for Gilead, Vanda and YM BioSciences.

Analysts' Upgrades, Downgrades: Elan

See who made what calls.

Mint Money Like Lone Star Capital

Here are some ideas to piggyback the private equity firm.

Health Winners & Losers: Elan

Pharmaceutical makers outpaced biotech stocks on Monday.

Cramer's Take on Top-Searched Stocks

Cramer's Take on Top-Searched Stocks

Bank of America is among the most-searched stocks on TheStreet.com. Here's what Cramer had to say about it recently.

Rocket Stocks for the Week

Rocket Stocks for the Week

These heavily shorted stocks have the potential to move higher in the coming days.

Health Winners & Losers: Biogen

Health Winners & Losers: Biogen

Biogen sinks on Tysabri-related news.

Stocks Derailed by GM, Factory Data

Stocks Derailed by GM, Factory Data

The market had risen earlier after the Labor Department's jobs report came in better than expected. Simon Constable reviews the session in The Real Story (above).

Unconfirmed PML Cases Dent Biogen, Elan

Unconfirmed PML Cases Dent Biogen, Elan

A conference call does little to allay investor fears that more incidents of the serious brain infection could emerge in Tysabri patients.

Feuerstein's Biotech-Stock Mailbag: Elan

Feuerstein's Biotech-Stock Mailbag: Elan

Revaluing a severely beaten Elan. And wanted: Your votes on best biotech CEO.

Brain Infections Sink Elan, Biogen

Brain Infections Sink Elan, Biogen

Two confirmed cases of PML in patients treated with Tysabri sends both stocks spiraling downward.

Biotech Stocks Burn Higher on M&A Fire

The sector is trading higher on today's buyout bid. One analyst offers a list of who else could tie the knot in the drug and biotech space.

Health Winners & Losers: Elan

Elan and Wyeth sink on study results of Alzheimer's treatment bapineuzumab.

Elan-Wyeth Alzheimer's Data Spook Bulls

The stocks sell off after the presentation of underwhelming and inconclusive study results of bapineuzumab. Let's break it down.

Alzheimer Drug Data Slam Elan, Wyeth

The drug stocks tumble on weak results from a much-anticipated phase II study of bapineuzumab.

Health Winners & Losers: Elan

Elan slips despite a narrowed second-quarter loss and strong Tysabri sales.

Biogen Beats Estimates, Raises Guidance

The biotech beats Wall Street estimates by 7 cents a share as sales of Tysabri and Rituxan surge.

Health Winners & Losers: Momenta

Health Winners & Losers: Momenta

Momenta Pharma gains on FDA action.

Health Winners & Losers: Insmed

Insmed climbs on study results.

Controversy Shadows Medivation (Update)

Controversy Shadows Medivation (Update)

Phase II study results show Dimebon improves the mental status of Huntington's disease patients, but a clerical error in previous regulatory filings misstated the study's endpoints.

Medivation Climbs on Dimebon Study Data

Medivation Climbs on Dimebon Study Data

The phase II study results show the experimental drug improves the mental status of patients with Huntington's disease.

Biotech Stocks: Second-Half '08 Preview

Biotech Stocks: Second-Half '08 Preview

Here are the data and regulatory decisions that are likely to be the biggest catalysts from July to December.

'Fast Money' Portfolios of the Week

Here are some of the stocks the crew has been talking about lately.

Feuerstein's Biotech-Stock Mailbag: Panacos

Confessions of a former Panacostal; weighing Indevus' chances after its latest FDA blow; and more Elan.